Alzheimer's disease (AD) is a progressive and fatal neurological illness. It produces changes in the brain that include loss of cells and accumulation of abnormal protein deposits. Initial symptoms are cognitive, with deficiencies in short-term memory the most common symptom. As the disease progresses so does the severity of cognitive deficiency. Loss of speech and immobility occur in the terminal stages There is no cure for AD and no marketed treatment that modifies the underlying disease process. Available therapies improve some symptoms of AD by increasing brain concentrations of molecules involved in cognition. ST101 differs from marketed therapies in that it has demonstrated two actions in animal research testing. It improves cognition and it also reduces the accumulation of abnormal protein deposits in the brain. These two properties suggest that ST101 may be a promising agent for the treatment of AD. This study is designed as a preliminary dose exploration/proof-of¬concept investigation of the ability of ST101 to improve cognition during 12 weeks of administration.
Ages Eligible for Study: 50 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Diagnostic evidence of mild to moderate Alzheimer's disease.
CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology.
A reliable and capable caregiver.
Subjects who reside in a skilled nursing facility.
Subjects with B12 or folate deficiency.
Subjects with chronic hepatic disease.
Subjects with a recent history of hematologic/oncologic disorders.
Subjects who have experienced a myocardial infarction with the past year.
Dementia caused or complicated by other organic disease
Go here to check the list of participating locations.
Responsible Party: Sonexa Therapeutics, Inc. ( Barbara Finn/Sr. VP Regulatory Affairs and QA )
Study ID Numbers: ST101-A001-202
Study First Received: February 10, 2009
Last Updated: February 11, 2009
ClinicalTrials.gov Identifier: NCT00842816 history of changes since first registered
Health Authority: United States: Food and Drug Administration
Study placed in the following topic categories:
Delirium, Dementia, Amnestic, Cognitive Disorders
Central Nervous System Diseases
Information provided by Sonexa Therapeutics, Inc.
Previously on the Alzheimer's Reading Room
- A Simple Three Minute Test Can Detect the Earliest Stage of Alzheimer's Disease
- Five Ways to Keep Alzheimer's Away
- High cholesterol levels in your 40s raises Alzheimer's risk
- Is Alzheimer's a type of diabetes of the brain?
- Ten Million Baby Boomers likely to suffer from Alzheimer’s during their lifetime
- Alzheimer's Disease Facts and Figures 2008
- Is Mild Cognitive Impairment (MCI) an Early Stage of Alzheimer's
- Is Etanercept the Cure for Alzheimer's